BMS terminates Phase I/II of ulocuplumab plus Opdivo

According to ClinicalTrials.gov, Bristol-Myers Squibb Co. (NYSE:BMY) terminated the Phase I/II CXCessoR4 trial evaluating ulocuplumab (BMS-936564) plus Opdivo nivolumab in about 36 patients with small cell lung cancer (SCLC) or pancreatic cancer due to “lack of efficacy in the short term acute phase.”

The open-label, U.S. and Finnish trial’s co-primary endpoints were dose-limiting toxicities (DLTs), objective response rate (ORR) and overall survival (OS). Secondary endpoints included safety and progression-free survival (PFS)...